Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
AffiliationDepartment of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal
MetadataShow full item record
AbstractDespite recent advances, prognosis of patients with advanced lung cancer remains dismal. Owing to a better understanding of the interactions between immune system and tumor cells, immunotherapy has emerged as a promising therapeutic strategy. After the recent approval of nivolumab and the promising results with other immune checkpoint inhibitors, combination strategies are now subject of intensive research. Notwithstanding these successes, immunotherapy still holds significant drawbacks. As the target shifts from tumor cells to the tumor microenvironment, treatment paradigms are changing and several improvements are needed for optimal use in clinical practice. Robust biomarkers for patient selection and a reliable way of evaluating treatment response are high priorities. Herein we review current data on immune checkpoint inhibitors for lung cancer treatment.
CitationImmunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. 2016, 12 (4):551-64 Future Oncol
- Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
- Authors: Marrone KA, Brahmer JR
- Issue date: 2016 Mar-Apr
- Checkpoint inhibitors in breast cancer: hype or promise?
- Authors: McArthur HL
- Issue date: 2016 Jun
- Immune checkpoint inhibitors in lung cancer: past, present and future.
- Authors: Seetharamu N, Budman DR, Sullivan KM
- Issue date: 2016 May
- Immune checkpoint inhibitors in NSCLC.
- Authors: Johnson DB, Rioth MJ, Horn L
- Issue date: 2014 Dec
- [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
- Authors: Bílek O, Bohovicová L, Demlová R, Poprach A, Lakomý R, Zdražilová-Dubská L
- Issue date: Fall 2016